Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 1,130,000 shares, an increase of 505.2% from the January 31st total of 186,700 shares. Currently, 13.7% of the company’s stock are short sold. Based on an average daily volume of 920,700 shares, the days-to-cover ratio is presently 1.2 days.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Virtu Financial LLC grew its stake in Genprex, Inc. (NASDAQ:GNPX) by 64.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,424 shares of the company’s stock after purchasing an additional 31,400 shares during the quarter. Virtu Financial LLC owned approximately 0.95% of Genprex worth $68,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Stock Performance

GNPX traded up $0.00 during trading on Friday, hitting $0.38. 469,464 shares of the company’s stock were exchanged, compared to its average volume of 1,018,017. The business’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.85. Genprex has a fifty-two week low of $0.28 and a fifty-two week high of $5.41.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.